Clinical development /
Phase I-IV. services
We provide exceptional study design, management, monitoring, and reporting expertise for our partners to support their confident decisions for successful clinical development. Our network in the medical community of the CEE Region and long-term KOL connections ensure optimal trial site selection and enrolment rates for our Clients.
Explore how we lead our Sponsors to Success in Phase I-IV. clinical development
COVID-19 medication study for a Korean Sponsor
HungaroTrial successfully managed a phase II./III. clinical trial for a Korean Sponsor researching a new COVID-19 medication. The trial was based in Serbia and Macedonia. HungaroTrial managed to enrol 103 patients in just 11 days, ensuring a timely completion of the study. HungaroTrial managed to
- secure fast track approvals in both countries
- ensure a quick start-up, including fast contract signature
- select excellent sites with proven enrolment potential
- conduct fast data base cleaning for interim analyses (85% of the study data were generated in 28 days and cleaned in less than 1 month).
Phase I study in Peripheral Arterial Occlusion (PAO)
A US-based biotech company initiated a Phase I. clinical trial in the US, South Africa and Brazil to develop a compound for the treatment of Peripheral Arterial Occlusion.
Since the enrolment rate was far below the expectations of upper management, the Sponsor decided to extend the project to three Central and Eastern European countries with the help of HungaroTrial.We managed to set up new trial sites in Hungary, Serbia and Romania within a short time. Due to the high activity and productivity of the trial sites, the average time to close a cohort was reduced from 157 days to 64 days. In this way HungaroTrial made it possible for the Sponsor to save one year of development time.
This success of the Phase I trial led HungaroTrial to win the Phase II study of this development program.
Phase III. study in Hypoparathyroidism indication
A US-based biotech company contacted HungaroTrial to execute a rescue project. The study began in the United States, but enrolment figures were far below the planned rate. Since the indication was for a rare disease and patient selection criteria were very limiting, it proved extremely difficult to find suitable trial sites and subjects.
Fortunately, HungaroTrial was able to quickly set up the project in Hungary, enrolling 26 patients instead of the contracted 18 patients- a 144% improvement over based on initial targets
Advance Your Program Today
HungaroTrial is ready to help you complete your clinical trial program on time and to the highest standards.
Medical device trials and Colsultancy
HungaroTrial’s Expert Team is ready to assist medical device companies through all phases of product development by regulatory consultancy and clinical trial services, with special focus on MDD => MDR transition.
For over 20 years HungaroTrial has provided CRA sourcing services in most CEE countries. The best proof of our service’s quality is the long list of our repeat clients, including 7 of the TOP 10 global pharmaceutical companies.
Support for COVID-19 research
From the beginning of the pandemic, HungaroTrial has been very active in COVID-19 clinical research. Our colleagues are dedicated to add our clinical development knowledge, medical expertise and research infrastructure to the global efforts to find safe and effective COVID-19 medications.